Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol

BACKGROUND: The intensive study of predictive factors has strongly ameliorated the therapeutic flow-chart of metastatic colorectal cancer (mCRC) by allowing the selection of patients who benefit from specific therapies. For instance, in mRAS (mutated RAS) mCRC patients, anti-EGFR drugs (cetuximab an...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Adv Med Oncol
Autors principals: Ottaiano, Alessandro, Scala, Stefania, Santorsola, Mariachiara, Trotta, Anna Maria, D’Alterio, Crescenzo, Portella, Luigi, Clemente, Ottavia, Nappi, Anna, Zanaletti, Nicoletta, De Stefano, Alfonso, Avallone, Antonio, Granata, Vincenza, Notariello, Carmen, Luce, Amalia, Lombardi, Angela, Picone, Carmine, Petrillo, Antonella, Perri, Francesco, Tatangelo, Fabiana, Di Mauro, Annabella, Albino, Vittorio, Izzo, Francesco, Rega, Daniela, Pace, Ugo, Di Marzo, Massimiliano, Chiodini, Paolo, De Feo, Gianfranco, Del Prete, Paola, Botti, Gerardo, Delrio, Paolo, Caraglia, Michele, Nasti, Guglielmo
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2021
Matèries:
Study Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8010802/
https://ncbi.nlm.nih.gov/pubmed/33854566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835921989223
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars